Market Overview:
The global PDE inhibitors market is expected to reach USD XX million by 2030, at a CAGR of XX% during the forecast period 2018-2030. The market growth is attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the pharmaceutical industry. Based on type, the global PDE inhibitors market is segmented into PDE5 inhibitors, PDE4 inhibitors, and others. The PDE5 inhibitor segment accounted for a major share of the global market in 2017 and is projected to grow at a high CAGR during the forecast period. This can be attributed to factors such as increasing incidence of erectile dysfunction (ED) and rising awareness about these drugs among consumers. Based on application, the global market is segmented into genitourinary diseases, cardiovascular diseases (CVDs), dermatological disorders, respiratory diseases (RD), schizophrenia & Alzheimer’s disease; Huntington’s disease; others). In 2017,,the genitourinary applications segment accounted for a major share of this market owing to an increase in incidence rates of urinary tract infections (UTIs) across all regions worldwide.
Product Definition:
PDE inhibitors are a class of drugs that block the activity of phosphodiesterase enzymes. This results in an increase in the levels of cyclic guanosine monophosphate (cGMP), which leads to smooth muscle relaxation and increased blood flow. PDE inhibitors are used to treat a variety of conditions, including erectile dysfunction, pulmonary hypertension, and Raynaud's phenomenon.
PDE5:
PDE5 is a phosphodiesterase enzyme that exists in two forms, namely PDE5A and PDE5B. Phosphodiesterase enzymes are used by cells to breakdown the second messenger cyclic adenosine monophosphate (cAMP) into free cAMP and GDP.
PDE4:
PDE4 is a type of phosphodiesterase enzyme that acts as an important regulator in the body. PDE4 inhibitors are medicines that decrease the activity of this enzyme and thus increase the levels of cGMP by inhibiting phosphodiesterase 4 (PDE4). The increased levels of cGMP lead to increased blood flow, which results in improved erection quality and duration.
Application Insights:
The global market is segmented by application into genitourinary, cardiovascular diseases, dermatological disorders, respiratory diseases, and schizophrenia. The genitourinary disorders segment dominated the overall market in terms of revenue in 2017. This can be attributed to the high prevalence of men¢â‚¬â„¢s health issues such as erection problems and impotence which are caused due to PDE5 inhibitors non-use or improper use.
PDE5 inhibitors are used for treating erectile dysfunction (ED) as well as impotence caused due to PDE5 inhibition. These drugs have a positive impact on both short-term and long-term sexual function which includes ability to achieve an erection sufficient for intercourse or ejaculation control respectively. In addition these drugs also improve libido especially in men suffering from ED who were advised by their physicians regarding its treatment with PDE5 inhibitor pills.
Regional Analysis:
North America dominated the global market in 2017. The growth of this region can be attributed to rising product consumption, increasing R&D activities, and presence of key manufacturers. In addition, growing awareness about sexual health and high prevalence of erectile dysfunction among aging population are some other factors driving the market for PDE inhibitors in this region.
Asia Pacific is expected to witness lucrative growth over the forecast period owing to rise in disposable income leading to increased demand for medicines especially medicines related to sexual health. This has resulted into an increase in international trade with countries such as Japan and China being major suppliers due to low manufacturing cost coupled with easy availability of raw materials such as sildenafil citrate which is a generic version of Viagra (sildenafil).
Growth Factors:
- Increasing incidence of chronic diseases such as cancer, diabetes, and heart diseases is expected to drive the demand for PDE inhibitors over the forecast period.
- Growing geriatric population is also anticipated to boost the market growth owing to increasing prevalence of age-related disorders such as Alzheimer’s disease and Parkinson’s disease that are treated with PDE inhibitors.
- Rising awareness about the benefits of PDE inhibitors in treating various chronic conditions is projected to propel market growth during the forecast period.
- Technological advancements in drug discovery and development are likely to provide lucrative opportunities for players operating in this market over the next few years.
Scope Of The Report
Report Attributes
Report Details
Report Title
PDE Inhibitors Market Research Report
By Type
PDE5, PDE4, Viagra, Cialis, Levitra, Others
By Application
Genitourinary, Cardiovascular Diseases, Dermatological Disorders, Respiratory Diseases, Schizophrenia, Alzheimer’S Disease, Huntington’S Disease, Others
By Companies
Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer, BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritech Biopharm, Otsuka, Chiesi Farmaceutici, Verona Pharma
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
140
Number of Tables & Figures
98
Customization Available
Yes, the report can be customized as per your need.
Global PDE Inhibitors Market Report Segments:
The global PDE Inhibitors market is segmented on the basis of:
Types
PDE5, PDE4, Viagra, Cialis, Levitra, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Genitourinary, Cardiovascular Diseases, Dermatological Disorders, Respiratory Diseases, Schizophrenia, Alzheimer’S Disease, Huntington’S Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Hanmi Science Holding
- Boehringer Ingelheim
- Takeda Pharmaceuticals
- AstraZeneca
- Bayer
- Celgene
- Eli Lilly
- Pfizer
- BioCrea
- Dart NeuroScience
- Carinopharm
- CTC Bio
- FORUM Pharmaceuticals
- Intra-Cellular Therapies
- Omeros Corporation
- Medimetriks Pharmaceuticals
- NuSirt Biopharma
- Palobiopharma
- Roivant Sciences
- Sagene Pharmaceuticals
- Tetra Discovery Partners
- Tritech Biopharm
- Otsuka
- Chiesi Farmaceutici
- Verona Pharma
Highlights of The PDE Inhibitors Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- PDE5
- PDE4
- Viagra
- Cialis
- Levitra
- Others
- By Application:
- Genitourinary
- Cardiovascular Diseases
- Dermatological Disorders
- Respiratory Diseases
- Schizophrenia
- Alzheimer’S Disease
- Huntington’S Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the PDE Inhibitors Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
PDE inhibitors are medications that block the activity of PDEs. This can help improve blood flow and sexual function in men and women.
Some of the key players operating in the pde inhibitors market are Hanmi Science Holding, Boehringer Ingelheim, Takeda Pharmaceuticals, AstraZeneca, Bayer, Celgene, Eli Lilly, Pfizer, BioCrea, Dart NeuroScience, Carinopharm, CTC Bio, FORUM Pharmaceuticals, Intra-Cellular Therapies, Omeros Corporation, Medimetriks Pharmaceuticals, NuSirt Biopharma, Palobiopharma, Roivant Sciences, Sagene Pharmaceuticals, Tetra Discovery Partners, Tritech Biopharm, Otsuka, Chiesi Farmaceutici, Verona Pharma.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 PDE Inhibitors Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 PDE Inhibitors Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 PDE Inhibitors Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the PDE Inhibitors Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global PDE Inhibitors Market Size & Forecast, 2018-2028
4.5.1 PDE Inhibitors Market Size and Y-o-Y Growth
4.5.2 PDE Inhibitors Market Absolute $ Opportunity
Chapter 5 Global PDE Inhibitors Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 PDE Inhibitors Market Size Forecast by Type
5.2.1 PDE5
5.2.2 PDE4
5.2.3 Viagra
5.2.4 Cialis
5.2.5 Levitra
5.2.6 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global PDE Inhibitors Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 PDE Inhibitors Market Size Forecast by Applications
6.2.1 Genitourinary
6.2.2 Cardiovascular Diseases
6.2.3 Dermatological Disorders
6.2.4 Respiratory Diseases
6.2.5 Schizophrenia
6.2.6 Alzheimer’S Disease
6.2.7 Huntington’S Disease
6.2.8 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global PDE Inhibitors Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 PDE Inhibitors Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America PDE Inhibitors Analysis and Forecast
9.1 Introduction
9.2 North America PDE Inhibitors Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America PDE Inhibitors Market Size Forecast by Type
9.6.1 PDE5
9.6.2 PDE4
9.6.3 Viagra
9.6.4 Cialis
9.6.5 Levitra
9.6.6 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America PDE Inhibitors Market Size Forecast by Applications
9.10.1 Genitourinary
9.10.2 Cardiovascular Diseases
9.10.3 Dermatological Disorders
9.10.4 Respiratory Diseases
9.10.5 Schizophrenia
9.10.6 Alzheimer’S Disease
9.10.7 Huntington’S Disease
9.10.8 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe PDE Inhibitors Analysis and Forecast
10.1 Introduction
10.2 Europe PDE Inhibitors Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe PDE Inhibitors Market Size Forecast by Type
10.6.1 PDE5
10.6.2 PDE4
10.6.3 Viagra
10.6.4 Cialis
10.6.5 Levitra
10.6.6 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe PDE Inhibitors Market Size Forecast by Applications
10.10.1 Genitourinary
10.10.2 Cardiovascular Diseases
10.10.3 Dermatological Disorders
10.10.4 Respiratory Diseases
10.10.5 Schizophrenia
10.10.6 Alzheimer’S Disease
10.10.7 Huntington’S Disease
10.10.8 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific PDE Inhibitors Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific PDE Inhibitors Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific PDE Inhibitors Market Size Forecast by Type
11.6.1 PDE5
11.6.2 PDE4
11.6.3 Viagra
11.6.4 Cialis
11.6.5 Levitra
11.6.6 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific PDE Inhibitors Market Size Forecast by Applications
11.10.1 Genitourinary
11.10.2 Cardiovascular Diseases
11.10.3 Dermatological Disorders
11.10.4 Respiratory Diseases
11.10.5 Schizophrenia
11.10.6 Alzheimer’S Disease
11.10.7 Huntington’S Disease
11.10.8 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America PDE Inhibitors Analysis and Forecast
12.1 Introduction
12.2 Latin America PDE Inhibitors Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America PDE Inhibitors Market Size Forecast by Type
12.6.1 PDE5
12.6.2 PDE4
12.6.3 Viagra
12.6.4 Cialis
12.6.5 Levitra
12.6.6 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America PDE Inhibitors Market Size Forecast by Applications
12.10.1 Genitourinary
12.10.2 Cardiovascular Diseases
12.10.3 Dermatological Disorders
12.10.4 Respiratory Diseases
12.10.5 Schizophrenia
12.10.6 Alzheimer’S Disease
12.10.7 Huntington’S Disease
12.10.8 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) PDE Inhibitors Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) PDE Inhibitors Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) PDE Inhibitors Market Size Forecast by Type
13.6.1 PDE5
13.6.2 PDE4
13.6.3 Viagra
13.6.4 Cialis
13.6.5 Levitra
13.6.6 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) PDE Inhibitors Market Size Forecast by Applications
13.10.1 Genitourinary
13.10.2 Cardiovascular Diseases
13.10.3 Dermatological Disorders
13.10.4 Respiratory Diseases
13.10.5 Schizophrenia
13.10.6 Alzheimer’S Disease
13.10.7 Huntington’S Disease
13.10.8 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 PDE Inhibitors Market: Competitive Dashboard
14.2 Global PDE Inhibitors Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Hanmi Science Holding
14.3.2 Boehringer Ingelheim
14.3.3 Takeda Pharmaceuticals
14.3.4 AstraZeneca
14.3.5 Bayer
14.3.6 Celgene
14.3.7 Eli Lilly
14.3.8 Pfizer
14.3.9 BioCrea
14.3.10 Dart NeuroScience
14.3.11 Carinopharm
14.3.12 CTC Bio
14.3.13 FORUM Pharmaceuticals
14.3.14 Intra-Cellular Therapies
14.3.15 Omeros Corporation
14.3.16 Medimetriks Pharmaceuticals
14.3.17 NuSirt Biopharma
14.3.18 Palobiopharma
14.3.19 Roivant Sciences
14.3.20 Sagene Pharmaceuticals
14.3.21 Tetra Discovery Partners
14.3.22 Tritech Biopharm
14.3.23 Otsuka
14.3.24 Chiesi Farmaceutici
14.3.25 Verona Pharma
